Printer Friendly

Elorac receives US patent for acne therapy.

M2 EQUITYBITES-February 7, 2014-Elorac receives US patent for acne therapy

(C)2014 M2 COMMUNICATIONS http://www.m2.com

Elorac, a specialty pharmaceutical company focused on the treatment of dermatological disorders, has received US patent No. 8,604,047, entitled 'Method and Composition for Treating Nodulocystic and Conglobate Acne Vulgaris' from the US Patent and Trademark Office, it was reported yesterday.

The patent offers once-weekly oral administration of selective inhibitors of type 1 and/or type 2 isoforms of steroid 5a-reductase, to patients with nodulocystic and conglobate acne vulgaris.

Elorac president and CEO, Dr Jeffrey Bernstein, said, 'We believe our product has many advantages over existing therapies for nodulocystic or conglobate acne.'

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 7, 2014
Words:122
Previous Article:Credit Union West picks Symitar Episys solution.
Next Article:Baywa subsidiary in talks to buy New Zealand's Apollo Apples.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters